Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (Nasdaq: LTRN) will host a live investor and analyst briefing on April 9, 2026 at 8:30 AM ET featuring a demonstration of withZeta.ai, a multi-agentic AI co-scientist for rare cancer drug discovery, development, and trial design.
The webcast will cover platform capabilities, commercial subscription model, competitive positioning, and near-term revenue strategy. Lantern cites 12 FDA designations, three drugs in precision oncology trials and over 100 patients dosed as part of the platform’s clinical heritage.
Lantern Pharma (NASDAQ: LTRN) reported 2025 operational and financial results, highlighting clinical progress across LP-300, LP-184, LP-284 and IND clearance for STAR-001, RADR® platform expansion and launch of withZeta.ai.
Key metrics: $10.1M cash at year-end, 48% LP-184 clinical benefit rate at therapeutic doses, LP-300 safety lead-in showing 86% clinical benefit and 43% objective response in initial U.S. patients.
Lantern Pharma (NASDAQ: LTRN) confirmed that Panna Sharma remains President, CEO, and director after a false third‑party article claimed he stepped down. The board affirmed confidence, cited a recently cleared IND for STAR-001 pediatric CNS trial, and warned of potential market manipulation while investigating and considering legal and regulatory referrals.
The company reiterated reliance on official SEC filings and its investor site and noted a webcast on March 30, 2026 at 4:30 p.m. ET to review FY2025 results.
Lantern Pharma (NASDAQ: LTRN) and Starlight Therapeutics announced FDA clearance of IND No. 179145 to initiate a planned Phase 1 pediatric CNS trial of STAR-001 (LP-184). The multicenter study will test STAR-001 as monotherapy and with spironolactone across relapsed/refractory ATRT, DIPG, GBM, medulloblastoma, and ependymoma, enrolling ~18–42 patients at POETIC sites. Preclinical data showed ERCC3 protein reduction ≥50% and a combination survival benefit (median 27 to 76 days, +181%, p=0.0018). Trial initiation is subject to additional funding.
Lantern Pharma (NASDAQ: LTRN) will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 2026 at 4:30 p.m. ET.
Management will discuss results for the period ended December 31, 2025, upcoming milestones, clinical trials, and developments of the RADR® AI platform. A replay will be available on the investor relations website.
Lantern Pharma (NASDAQ: LTRN) announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit in Boston on February 17–19, 2026. The presentation is scheduled for February 19, 2026 at 10:30 a.m. ET.
Lantern will describe how its RADR AI platform supported development of STAR-001/LP-184, creation of subsidiary Starlight Therapeutics, and work on CNS cancers including recurrent glioblastoma and pediatric ATRT. STAR-001 has FDA Orphan Drug and Rare Pediatric Disease designations.
Lantern Pharma (NASDAQ: LTRN) announced that the FDA granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas on January 20, 2026. The designation is Lantern’s third for LP-284 and sixth overall for its pipeline, and could provide 7 years of U.S. market exclusivity if approved plus tax credits and user-fee exemptions. LP-284 targets DNA repair deficiencies via a synthetic lethal TC-NER mechanism. Lantern cites ~96,200 global annual soft tissue sarcoma cases and a seven‑market therapeutic value of ~$2.4 billion in 2025 (projected to ~$4.7 billion by 2035). LP-284 remains in a Phase 1 trial (NCT06132503) with early single-patient clinical activity reported.
Lantern Pharma (NASDAQ: LTRN) announced an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India to industrialize and scale its RADR® platform for oncology and other diseases. The center will expand data engineering, ML-ready disease models, specialized LLM and LQM development, and follow-the-sun development with US integration. Lantern says hiring is underway and expects the expansion to be cash flow neutral in Q1 2026. The company plans phased deployment (oncology first, then inflammation/immunology/neurodegeneration) and will host an Investor & Analyst Day on Jan 22, 2026.
Lantern Pharma (NASDAQ: LTRN) reported additional Phase 1a results for biomarker-activated drug candidate LP-184, showing a 54% disease control rate at or above therapeutic dose levels in 63 heavily pre-treated advanced solid tumor patients (median 3+ prior therapies).
The study met all primary endpoints for safety and tolerability and established a recommended Phase 2 dose (RP2D) of 0.39 mg/kg IV on Days 1 and 8 of a 21-day cycle, with a reported therapeutic window of ~2.45-fold. More than 87% of patients exceeded the PTGR1 bioactivation threshold; several patients show durable benefit of 12+ to 23+ months. LP-184 holds multiple FDA designations (3 Orphan, 2 Fast Track, Pediatric Rare Disease) and Lantern plans multiple biomarker-guided Phase 1b/2 trials across TNBC, GBM, NSCLC, and urothelial carcinoma.
Lantern Pharma (NASDAQ: LTRN) reported Q3 2025 results and clinical progress on November 13, 2025. Key clinical milestones include LP-184 Phase 1a achieving all primary endpoints with a 48% clinical benefit rate at/above the therapeutic dose and an RP2D of 0.39 mg/kg. FDA Type C meeting provided regulatory guidance for a pediatric ATRT program and confirmed a spironolactone combination strategy. LP-300 Phase 2 HARMONIC™ enrollment and LP-284 data presentation advanced partnership discussions. RADR® AI modules demonstrated commercial readiness. Financials: cash and equivalents ~$12.4M as of Sept 30, 2025, providing runway into ~Q3 2026. Webcast scheduled Nov 13, 2025.